What is the role of lenvatinib in the treatment of anaplastic thyroid carcinoma?

Role of Lenvatinib in Anaplastic Thyroid Carcinoma

Lenvatinib combined with pembrolizumab is the preferred first-line systemic therapy for metastatic anaplastic thyroid carcinoma (ATC), particularly in patients with high PD-L1 expression (≥50%) or elevated tumor mutational burden, where complete responses have been documented. 1

Primary Treatment Approach

For patients with metastatic ATC requiring systemic therapy, the treatment algorithm prioritizes:

First-Line: Combination Immunotherapy + TKI

• Lenvatinib plus pembrolizumab achieves a 66% complete response rate in retrospective data, with median PFS of 16.5 months 1
• This combination is most effective when:
  • PD-L1 tumor proportion score (TPS) >50%
  • Elevated tumor mutational burden (TMB)
  • Patient can tolerate dual therapy toxicity profile

Monotherapy Lenvatinib

When combination therapy is not feasible, lenvatinib monotherapy demonstrates:

• Objective response rate: 24-33% 2, 3
• Median overall survival: 5.0-10.6 months 3, 2
• Median progression-free survival: 1.7-7.4 months 2, 4

The FDA-approved dose is 24 mg once daily 5, though real-world data suggest reduced initial dosing may provide therapeutic benefit with better tolerability 4.

Clinical Context and Nuances

When Lenvatinib Works Best

Lenvatinib shows superior outcomes in ATC patients with:

• Unresectable primary tumors without distant metastases
• Adequate performance status (ECOG 0-2)
• Good nutritional status (CONUT score ≤2 predicts significantly longer OS and PFS) 6
• No prior total thyroidectomy (80% develop hypothyroidism requiring management) 7

Conversion Surgery Strategy

For initially unresectable ATC, lenvatinib can enable conversion surgery within 13 days of treatment initiation 8. This approach:

• Reduces tumor size sufficiently for R0/R1 resection
• Prevents life-threatening complications (asphyxia, fistula, hemorrhage)
• Requires lenvatinib withdrawal 7 days before surgery to minimize wound healing complications 8
• Histopathology shows approximately 70% of tumor converted to granulation tissue 8

Dosing Algorithm

Start with 24 mg daily unless:

• Age >70 years with multiple comorbidities → consider 18-20 mg daily 4
• Body weight <60 kg → consider dose reduction
• Severe renal impairment → dose reduction required 5
• Severe hepatic impairment (Child-Pugh C) → dose reduction required 5

The 2025 ESMO guidelines emphasize that higher doses correlate with greater efficacy - a randomized trial showed 57.3% ORR with 24 mg versus 40.3% with 18 mg in differentiated thyroid cancer 9. However, real-world ATC data suggest reduced initial dosing (median OS 6.2 months vs 2.0 months with standard dose) may benefit patients unable to tolerate full-dose therapy 4.

Critical Safety Considerations

Common Treatment-Emergent Adverse Events (occur in >50% of patients):

• Hypertension (80-82%)
• Decreased appetite (80-82%)
• Fatigue (59-80%)
• Diarrhea (40-59%)
• Proteinuria (59%)
• Hypothyroidism (80% in patients with intact thyroid) 7

Management Strategy

• Dose interruptions and reductions are standard practice - only 1 of 17 ATC patients required permanent discontinuation in phase 2 trials 2
• Monitor thyroid function closely in patients without prior total thyroidectomy
• Hold lenvatinib at least 7 days before any surgical procedure 5
• Avoid in patients with untreated CNS metastases due to bleeding risk 1

Alternative Options When Lenvatinib Fails

The NCCN 2025 guidelines recommend the following hierarchy 1:

1. PD-1 inhibitors (spartalizumab showed 19% ORR, higher in PD-L1+ disease at 29-35%) 1
2. Paclitaxel monotherapy (60-90 mg/m² IV weekly for stage IVB disease)
3. Doxorubicin + cisplatin (based on small randomized trial data)
4. Paclitaxel + carboplatin or docetaxel + doxorubicin (category 2B, lower evidence quality)

Key Clinical Pitfalls to Avoid

• Do not delay treatment - ATC has extremely rapid progression; median OS without lenvatinib is 2.0 months 3
• Do not use lenvatinib as monotherapy if combination with pembrolizumab is feasible - the combination shows dramatically superior outcomes (66% CR vs 24-33% ORR) 1, 2
• Do not continue full-dose therapy through intolerable toxicity - dose modifications maintain efficacy while improving tolerability 2, 4
• Do not perform surgery without adequate lenvatinib washout period - minimum 7 days required to reduce fistula and wound healing complications 8